Atomoxetine hydrochloride + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Attention Deficit Hyperactivity Disorder
Conditions
Attention Deficit Hyperactivity Disorder
Trial Timeline
Aug 1, 2007 → Feb 1, 2009
NCT ID
NCT00510276About Atomoxetine hydrochloride + Placebo
Atomoxetine hydrochloride + Placebo is a approved stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00510276. Target conditions include Attention Deficit Hyperactivity Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00700427 | Phase 3 | Completed |
| NCT00510276 | Approved | Completed |
| NCT00190879 | Approved | Completed |
| NCT00191945 | Phase 3 | Completed |
| NCT00191906 | Approved | Completed |
| NCT00190775 | Approved | Completed |
| NCT00190736 | Approved | Completed |
| NCT00485459 | Phase 3 | Completed |
| NCT00191698 | Phase 3 | Completed |
| NCT00190931 | Approved | Completed |
| NCT00191009 | Phase 2/3 | Completed |
| NCT00486122 | Approved | Completed |
Competing Products
20 competing products in Attention Deficit Hyperactivity Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Phase 3 | 77 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| CLONICEL (Clonidine HCl sustained release) | Shionogi | Phase 3 | 77 |
| Donepezil hydrochloride + Placebo | Eisai | Phase 3 | 77 |
| LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule) | Eli Lilly | Phase 2/3 | 65 |
| Atomoxetine + Placebo | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Pre-clinical | 23 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride + Placebo | Eli Lilly | Approved | 85 |
| atomoxetine | Eli Lilly | Phase 3 | 77 |
| atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride | Eli Lilly | Phase 3 | 77 |
| Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo | Eli Lilly | Phase 3 | 77 |